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INSTRUCTIONS TO AUTHORS1. Manuscript Submission
1.1. Online Submission
Manuscripts (meaning all submission items, 
including all text, tables, artwork, cover letter, 
conflicts of interest disclosures, and any other 
required documents/material) must be submitted 
online to the JFDA through the Elsevier Editorial 
System (EES) at http://ees.elsevier.com/jfda. If 
assistance is required, please refer to the tutorials 
for authors and/or customer support that are 
available on the EES website; you may also contact 
the Editorial Office. Please do not post, fax or e-mail 
your manuscripts to the Editorial Office.
Editorial Office
Journal of Food and Drug Analysis (JFDA)
Food and Drug Administration, Ministry of Health 
and Welfare, R.O.C. (TFDA)
No. 161-2, Kunyang Street, Nangang District
Taipei City 115-61, Taiwan, R.O.C
Tel: (+886) 2-2787-7226
Fax: (+886) 2-2653-1283
E-mail: jfda@fda.gov.tw
1.2. Important Information
•	 	Articles	 should	 be	 in	Microsoft	Word	 document	
format and prepared in the simplest form possible. 
•	 	You	 may	 use	 automatic	 page	 numbering	 and	
line numbering, but do NOT use other kinds of 
automatic formatting such as footnotes, headers 
and footers. References especially should NOT 
be formatted using the MS Word “endnotes” 
or “footnotes” function; instead, you may use 
the commercially available EndNote® or 
Reference Manager® software to manage your 
references.
•	 	Put	 text,	 references,	 table	 headings	 and	 tables,	
and figure legends in one file. Each table heading 
and table (double spaced) should begin on a new 
page. Figure legends (double spaced) should also 
be on a new page.
•	 	Figures	 must	 be	 submitted	 as	 separate	 picture	
files, at the correct resolution and named 
according to the figure number and format, e.g., 
“Fig1.tif”, “Fig2.jpg”. Please see section 9.8. for 
more information.
1.3. Supporting Documents
The following documents must be included in your 
submission (refer also to the Checklist that follows these 
author instructions). Items (1) and (2) are mandatory. 
Items (3), (4), (5) and (6) are required only if they are 
applicable to your manuscript.
(1)  Cover Letter. This must include the following 
information:
•	 title	of	the	manuscript
•	 	names	(spelled	out	in	full)	of	all	the	authors*,	
and the institutions with which they are 
affiliated; indicate all affiliations with a 
superscripted lowercase letter after the 
author’s name and in front of the matching 
affiliation (*the name of each author should be 
written with the family name last, e.g., Wan-Lin 
Chang)
•	 	corresponding	 author	 details	 (name,	 e-mail,	
mailing address, telephone and fax numbers)
•	 	a	statement	that	the	material	contained	in	the	
manuscript has not been previously published 
and is not being concurrently submitted 
elsewhere
•	 	persons	 who	 do	 not	 fulfill	 the	 requirements	
to be listed as authors but who nevertheless 
contributed to the manuscript (such as those 
who provided writing assistance, for example) 
should be disclosed
•	 	list	of	manuscripts	that	have	been	published,	
submitted, or are in press that are similar 
to the submission to the JFDA (and include 
in your submission copies of those similar 
manuscripts so that JFDA Editors can be 
assured there is no overlap)
•	 	Optional: if you have a list of reviewers who you 
wish to review or not to review your manuscript, 
you may include this list in the cover letter
The Journal of Food and Drug Analysis (JFDA) is the official peer-reviewed publication of the Food and Drug 
Administration, Taiwan (TFDA). It is published quarterly by Elsevier in March, June, September and December. 
The Journal aims to publish original research and review papers on the analyses of food, drugs, medical 
devices, cosmetics and traditional Chinese medicine as well as related disciplines that are of topical interest 
to the public health profession.
Authors are welcome to submit reviews, original articles, case reports, and research notes for consideration.
The Editorial Board requires authors to be in compliance with the Uniform Requirements for Manuscripts 
Submitted to Biomedical Journals (URMs), which are compiled by the International Committee of Medical Journal 
Editors (ICMJE); current URMs are available at www.icmje.org.
These Instructions to Authors are revised periodically by the Editors as needed. Authors should consult a 
recent issue of the Journal or visit www.jfda-online.com for the latest version of these instructions. Any 
manuscript not prepared according to these instructions will be returned immediately to the author(s) 
without review.
(2)  Authorship & Conflicts of Interest Statement. 
Each author’s contribution to the manuscript 
should be listed. Any and all potential and actual 
conflicts of interest should also be listed (see 
Section 2 for more information). Please use the 
JFDA Authorship & Conflicts of Interest Statement 
form that follows these author instructions and 
that is also provided on the Journal’s website at 
www.jfda-online.com. Your signature and those 
of ALL your coauthors must be included.
(3)  Ethics Statement. Articles covering the use of 
human or animal samples in research, or human 
or animal experiments must be accompanied 
by a letter of approval from the relevant review 
committee or authorities. See Section 3 for more 
information.
(4)  Consolidated Standards of Reporting Trials 
(CONSORT) flow chart for randomized controlled 
trials submitted for publication. See Section 4 for 
more information.
(5)  Signed Statement of Informed Consent. Articles 
where human subjects can be identified in 
descriptions, photographs or pedigrees must be 
accompanied by a signed statement of informed 
consent to publish (in print and online) the 
descriptions, photographs and pedigrees from 
each subject who can be identified. See Section 5 
for more information.
(6)  Copyright Permission. If you have reproduced 
or adapted material from other copyrighted 
sources, the letter(s) of permission from the 
copyright holder(s) to reproduce or adapt 
the copyrighted sources must be supplied. 
Otherwise, such material must be removed from 
your manuscript.
2. Disclosure of Conflicts of Interest
A conflict of interest occurs when an individual’s 
objectivity is potentially compromised by a desire 
for financial gain, prominence, professional 
advancement or a successful outcome. JFDA 
Editors strive to ensure that what is published in 
the Journal is as balanced, objective and evidence-
based as possible. Since it can be difficult to 
distinguish between an actual conflict of interest 
and a perceived conflict of interest, the Journal 
requires authors to disclose all and any potential 
conflicts of interest.
Conflicts of interest may be financial or non-
financial. Financial conflicts include financial 
relationships such as honoraria; educational grants; 
participation in speakers’ bureaus; membership, 
employment, consultancies, stock ownership, or 
other equity interest; expert testimony or patent-
licensing arrangements. Non-financial conflicts 
include personal or professional relationships, 
affiliations, academic competition, intellectual 
passion, knowledge or beliefs that might affect 
objectivity.
Please ensure that the name of each author 
listed in your manuscript appears in either Section 
I or Section II on page 2 of the JFDA Authorship & 
Conflicts of Interest Statement form (an author’s name 
cannot appear in both Section I and Section II of the 
form).
3. Ethical Approval of Studies and Informed 
Consent
For human or animal experimental investigations, 
appropriate institutional review board or ethics 
committee approval is required, and such 
approval should be stated in the methods section 
of the manuscript. For those investigators who do 
not have formal ethics review committees, the 
principles outlined in the Declaration of Helsinki 
should be followed (World Medical Association. 
Declaration of Helsinki: ethical principles for medical 
research involving human subjects. Available at: 
www.wma.net/en/30publications/10policies/
b3/17c.pdf).
For investigation of human subjects, state 
explicitly in the methods section of the manuscript 
that informed consent was obtained from all 
participating adult subjects and from parents or 
legal guardians for minors or incapacitated adults, 
together with the manner in which informed 
consent was obtained (e.g., oral or written).
For work involving animals, the guidelines for 
their care and use that were followed should be 
stated in the methods section of the manuscript. 
For those investigators who do not have formal 
institutional guidelines relating to animal 
experiments, the European Commission Directive 
86/609/EEC for animal experiments (available at http://
ec.europa.eu/environment/chemicals/lab_animals/
legislation_en.htm) should be followed and the 
same should be stated in the methods section of 
the manuscript.
4. Reporting Clinical Trials
All randomized controlled trials submitted 
for publication should include a completed 
Consolidated Standards of Reporting Trials 
(CONSORT) flow chart (please go to www.consort-
statement.org for more information). The JFDA 
has adopted the ICMJE proposal that requires, as 
a condition of consideration for publication of 
clinical trials, registration in a public trials registry. 
Purely observational studies (those in which the 
assignment of the medical intervention is not at 
the discretion of the investigator) will not require 
registration. Further information can be found at 
www.icmje.org.
5. Identification of Patients in Descriptions, 
Photographs and Pedigrees
A signed statement of informed consent to 
publish (in print and online) patient descriptions, 
photographs and pedigrees should be obtained 
from all persons (parents or legal guardians for 
minors) who can be identified (including by the 
patients themselves) in such written descriptions, 
photographs or pedigrees. Such persons should 
be shown the manuscript before its submission. 
Omitting data or making data less specific to de-
identify patients is acceptable, but changing any 
such data is not acceptable. State explicitly in the 
methods section of the manuscript that informed 
consent was obtained from all participating adult 
subjects or from parents or legal guardians for 
minors or incapacitated adults, together with the 
manner in which informed consent was obtained 
(i.e., oral or written).
6. Previous Publication or Duplicate Submission
Submitted manuscripts are considered with the 
understanding that they have not been published 
previously in print or electronic format (except 
in abstract or poster form) and are not under 
consideration in totality or in part by another 
publication or electronic medium.
7. Basic Criteria
Articles should be written in English, using American 
English spelling, and meet the following basic 
criteria: the material is original, the information 
is important, the writing is clear and concise, the 
study methods are appropriate, the data are valid, 
and the conclusions are reasonable and supported 
by the data.
8. Article Categories
The categories of articles that are published in the 
Journal are listed and described below. Please select 
the category that best describes your paper. If your 
paper does not fall into any of these categories, 
please contact the Editorial Office.
8.1. Review Articles
These should aim to provide the reader with a 
balanced overview of an important and topical 
subject in the field, emphasizing factors such as 
cause, diagnosis, prognosis, therapy or prevention. 
They should cover aspects of a topic in which 
scientific consensus exists as well as aspects that 
remain controversial and are the subject of ongoing 
scientific research. All articles and data sources 
reviewed should include information about the 
specific type of study or analysis, population, 
intervention, exposure, and tests or outcomes. 
All articles or data sources should be selected 
systematically for inclusion in the review and 
critically evaluated. The text is usually less than 
5000 words, with not more than 50 references.
8.2. Invited Articles
The format for an invited article will be decided by 
JFDA Editors.
8.3. Original Articles
These articles typically include randomized trials, 
intervention studies, studies of screening and 
diagnostic tests, laboratory and animal studies, 
cohort studies, cost-effectiveness analyses, case-
control studies, and surveys with high response 
rates, which represent new and significant 
contributions to medical science.
Section headings should be: Abstract, Intro-
duction, Methods, Results, Discussion, Conflicts of 
Interest Statement (if any), Acknowledgments (if 
any), and References.
The Introduction should provide a brief 
background to the subject of the paper, explain the 
importance of the study, and state a precise study 
question or purpose.
The Methods section should describe the study 
design and methods (including the study setting 
and dates, patients/participants with inclusion 
and exclusion criteria, patient samples or animal 
specimens used, the essential features of any 
interventions, the main outcome measures, the 
laboratory methods followed, or data sources 
and how these were selected for the study), and 
state the statistical procedures employed in the 
research.
The Results section should comprise the 
study results presented in a logical sequence, 
supplemented by tables and/or figures. Take 
care that the text does not repeat data that are 
presented in tables and/or figures. Only emphasize 
and summarize the essential features of the main 
results.
The Discussion section should be used to 
emphasize the new and important aspects of the 
study, placing the results in context with published 
literature, the implications of the findings, and the 
conclusions that follow from the study results.
The text is usually less than 4000 words, with 
not more than 30 references.
8.4. Case Reports
These are short discussions of a case or case series 
with unique features not previously described that 
make an important teaching point or scientific 
observation. They may describe novel techniques 
or use of equipment, or new information on 
diseases of importance. Section headings should 
be: Abstract, Introduction, Case Report, Discussion, 
Acknowledgments (if any), and References.
The Introduction should describe the purpose of 
the present report, the significance of the disease 
and its specificity, and briefly review the relevant 
literature.
The Case Report should include the general 
data of the case, medical history, family 
history, chief complaint, present illness, clinical 
manifestation, methods of diagnosis and 
treatment, and outcome.
The Discussion should compare, analyze and 
discuss the similarities and differences between the 
reported case and similar cases reported in other 
published articles. The importance or specificity of 
the case should be restated when discussing the 
differential diagnoses. Suggest the prognosis of the 
disease and possibility of prevention.
The text is usually less than 1200 words, with 
not more than 10 references.
8.5. Research Notes
These should be concise presentations of 
preliminary experimental results or technical 
aspects of clinical or experimental practice that 
are not fully investigated, verified or perfected but 
which may be of widespread interest or application. 
The Research Note should be unstructured (i.e., in 
one single paragraph with no subheadings), of no 
more than 1500 words in length, with not more 
than 10 references and 1 figure/table.
9. Manuscript Preparation
Text should be typed double-spaced on white A4 
(297 – 210 mm) paper, with outer margins of 2.5 
cm. The manuscript should include a title page, 
abstract, keywords, text, conflicts of interest 
statement (if any), acknowledgments (if any), 
references, and figures and tables as appropriate. 
Each section of the manuscript should begin on a 
new page. Lines must be numbered consecutively 
throughout the manuscript. Other than the cover 
page, every page of the manuscript, including 
the title page, references and tables should be 
numbered.
All pages must be numbered consecutively, 
beginning with the title page and including tables 
and figures. Lines in the abstract and text should be 
numbered consecutively from beginning to end in a 
separate column at the left.
Font type:
•	 	Article	title:	 
bold 16-point Times New Roman font.
•	 	Section	headings:	 
italics 14-point Times New Roman font.
•	 	Main	text:	 
standard 12-point Times New Roman font.
•	 	Figure/table	legends:	 
standard 10-point Times New Roman font.
9.1. Title Page
The title page should contain the following 
information (in order, from the top to bottom of the 
page):
•	 article	category
•	 	article	title	(the	title	of	the	manuscript	should	be	
explicit, descriptive and as brief as possible—no 
more than 20 words in length)
•	 	names	(spelled	out	in	full)	of	all	the	authors*,	and	
the institutions with which they are affiliated; 
indicate all affiliations with a superscripted 
lowercase letter after the author’s name and in 
front	 of	 the	 matching	 affiliation	 (*the	 name	 of	
each author should be written with the family 
name last, e.g., Wan-Lin Chang)
•	 	corresponding	 author	 details	 (name,	 e-mail,	
mailing address, telephone and fax numbers)
9.2. Abstracts and Keywords
An unstructured abstract (i.e., in one single 
paragraph with no subheadings), of no more than 
500 words in length, and relevant keywords (no more 
than 5 words, in alphabetical order) are required 
for the following article categories: Review Articles, 
Original Articles, Case Reports, and Research Notes. 
Keywords should be taken from the Medical Subject 
Headings (MeSH) list of Index Medicus (www.nlm.
nih.gov/mesh/meshhome.html).
9.3. Graphical Abstract
A Graphical Abstract should allow readers to 
quickly gain an understanding of the main take-
home message of the paper and is intended to 
encourage browsing, promote interdisciplinary 
scholarship, and help readers identify more quickly 
which papers are most relevant to their research 
interests.
Authors must provide an image that clearly 
represents the work described in the paper. A 
key figure from the original paper, summarizing 
the content can also be submitted as a graphical 
abstract. Graphical Abstracts should be submitted 
as a separate file in EES by selecting "Graphical 
Abstracts" from the drop-down list when uploading 
files.
Graphical Abstracts will be displayed in online 
search result lists, the online contents list and the 
online article, but will not (yet) appear in the article 
PDF file or print.
For more detailed instructions please visit 
http://www.elsevier.com/authors/journal-authors/
graphical-abstract
9.4. Main Text
The text for Original Articles should be organized 
into the following sections: Introduction, 
Methods, Results, Discussion, Conflicts of Interest 
Statement (if any), Acknowledgments (if any), 
and References. Sections for Case Reports are: 
Introduction, Case Report, Discussion, Conflicts 
of Interest Statement (if any), Acknowledgments 
(if any), and References. Each section should 
begin on a new page.
9.4.1. Abbreviations
Where a term/definition will be continually referred 
to, it must be written in full when it first appears in 
the text, followed by the subsequent abbreviation 
in parentheses. Thereafter, the abbreviation 
may be used. An abbreviation should not be first 
defined in any section heading; if an abbreviation 
has previously been defined in the text, then the 
abbreviation may be used in a subsequent section 
heading. Restrict the number of abbreviations to 
those that are absolutely necessary.
9.4.2. Numbers
Numbers that begin a sentence or those that are 
less than 10 should be spelled out using letters. 
Centuries and decades should be spelled out, e.g. the 
Eighties or nineteenth century. Laboratory parameters, 
time, temperature, length, area, mass, and volume 
should be expressed using digits.
9.4.3. Units
Système International (SI) units must be used, e.g., 
cm, mm, mL, kg, g, mg, ng, ppm, °C, min, h, mmHg.
9.4.4. Names of drugs, devices and other products
Use the Recommended International Non-proprietary 
Name (rINN) for medicinal substances, unless the 
specific trade name of a drug is directly relevant to 
the discussion. Generic drug names should appear in 
lowercase letters in the text. If a specific proprietary 
drug needs to be identified, the brand name may 
appear only once in the manuscript in parentheses 
following the generic name the first time the drug is 
mentioned in the text.
For devices and other products, the specific 
brand or trade name, the manufacturer and their 
location (city, state, country) should be provided the 
first time the device or product is mentioned in the 
text, for example, “…IBM SPSS Statistics 21.0 was 
used	 (IBM	 Corp.,	 Armonk,	 NY,	 USA)”.	 Thereafter,	
the generic term (if appropriate) should be used.
9.4.5. Gene nomenclature
Current standard international nomenclature for 
genes should be adhered to. For human genes, 
use genetic notation and symbols approved 
by the HUGO Gene Nomenclature Committee 
(www.genenames.org).	 You	 may	 also	 refer	 to	
the resources available on PubMed at www.
ncbi.nlm.nih.gov/guide/genes-expression. The 
Human Genome Variation Society has a useful 
site that provides guidance in naming mutations 
at www.hgvs.org/mutnomen/index.html. In your 
manuscript, genes should be typed in italic font 
and include the accession number.
9.4.6. Statistical requirements
Statistical analysis is essential for all research 
papers except Case Reports. Use correct 
nomenclature for statistical methods (e.g., two 
sample t test, not unpaired t test). Descriptive 
statistics should follow the scales used in data 
description. Inferential statistics are important 
for interpreting results and should be described in 
detail.
All p values should be presented to the third 
decimal place for accuracy. The smallest p 
value that should be expressed is p < 0.001 since 
additional zeros do not convey useful information; 
the largest p value that should be expressed is p > 
0.99.
9.4.7. Personal communications and unpublished data
These sources cannot be included in the 
references list but may be described in the text. 
The author(s) must give the full name and highest 
academic degree of the person, the date of the 
communication, and indicate whether it was in 
oral or written (letter, fax, e-mail) form. A signed 
statement of permission should be included from 
each person identified as a source of information 
in a personal communication or as a source for 
unpublished data.
9.5. Conflicts of Interest Statement and/or Funding/
Support Statement
Since it is difficult to distinguish between an 
actual conflict of interest and a perceived conflict 
of interest, the JFDA requires authors to disclose 
all and any potential conflicts of interest and let 
readers judge for themselves. Therefore, please 
ensure that you provide information about any 
potential financial and non-financial conflicts of 
interest (see Section 2 for more information) in a 
concise paragraph after the main text.
All financial and material support for the 
research, work, writing and editorial assistance from 
internal or external agencies, including commercial 
companies, should be clearly and completely 
identified in a Funding/Support Statement.
9.6. Acknowledgments
After the Conflicts of Interest Statement and/
or Funding/Support Statement, general 
acknowledgments for consultations and statistical 
analyses should be listed concisely, including the 
names of the individuals who were directly involved. 
Consent should be obtained from those individuals 
before their names are listed in this section. Those 
acknowledged should not include secretarial, clerical 
or technical staff whose participation was limited to 
the performance of their normal duties.
9.7. References
Authors are responsible for the accuracy and 
completeness of their references and for correct in-
text citation.
9.7.1. In the main text, tables and figure legends
•	 	References	 should	 be	 indicated	 by	 numbers	 in	
square brackets in line with the text, numbered 
consecutively in order of appearance, and placed 
before punctuation. [The actual authors can be 
referred to, but the reference number(s) must 
always be given.]
•	 	References	cited	in	tables	or	figure	legends	should	
be included in sequence at the point where the 
table or figure is first mentioned in the main text.
•	 	Do	 not	 cite	 abstracts	 unless	 they	 are	 the	 only	
available reference to an important concept.
•	 	Do	not	cite	uncompleted	work	or	work	that	has	not	
yet been accepted for publication (i.e., “unpublished 
observation”, “personal communication”) as 
references. Also see Section 9.3.7.
9.7.2. In the references list
•	 	References	should	be	compiled	at	the	end	of	the	
manuscript according to the order of citation in 
the text.
•	 	References	should	be	limited	to	those	cited	in	the	
text only.
•	 	Journal	 references	 should	 include,	 in	 order,	
authors’ surnames and initials, article title, 
abbreviated journal name, year, volume (without 
the issue number) and inclusive page numbers.
•	  The surnames and initials of all the authors 
should be included.
•	 	Abbreviations	for	journal	names	should	conform	
to those used in MEDLINE.
•	 	If	citing	a	website,	provide	the	author	information,	
article title, website address and the date you 
accessed the information.
•	 	Reference	to	an	article	that	is	in	press	must	state	
the journal name and, if possible, the year and 
volume.
Examples of the most common reference types 
are provided below. (Please pay particular attention 
to the formatting, word capitalization, spacing and 
style.)
Standard journal article
[1]	 Hoog	 SL,	 Cheng	 Y,	 Elpers	 J,	 Dowsett	 SA.	
Duloxetine and pregnancy outcomes: Safety 
surveillance findings. Int J Med Sci 2013;10:413–9. 
Journal supplement
[2] Iemoli E, Trabattoni D, Parisotto S, Borgonovo L, 
Toscano M, Rizzardini G, Clerici M, Ricci E, Fusi A, 
De Vecchi E, Piconi S, Drago L. Probiotics reduce 
gut microbial translocation and improve adult 
atopic dermatitis. J Clin Gastroenterol 2012;46 
Suppl:S33–40.
Journal article not in English but with English abstract
[3] Liu M, Liu Z. Overview of clinical study on 
traditional Chinese medicine invigorating spleen 
and stomach, promoting blood circulation and 
remove blood stasis in treatment of chronic atrophic 
gastritis.	Zhongguo	Zhong	Yao	Za	Zhi	2012;37:3361-
4. [In Chinese, English abstract]
Book with edition
[4] Watson DG. Pharmaceutical analysis. 3rd ed. 
London: Churchill Livingstone; 2012.
Book with editors
[5] Liu J, Peck G, editors. Chinese dietary therapy. 
London: Churchill Livingstone; 1995.
Book chapter in book with editor and edition
[6] Greaves M, Culligan DJ. Blood and bone marrow. 
In: Underwood JCE, editor. General and systematic 
pathology. 4th ed. London: Churchill Livingstone; 
2004, p. 615–72.
Book series with editors
[7] Wilson JG, Fraser FC, editors. Handbook of 
teratology,	vols.	1–4.	New	York:	Plenum	Press;	1977–
1978.
Bulletin
[8] World Health Organization. World health report 
2002: Reducing risk, promoting healthy life. Geneva, 
Switzerland: World Health Organization; 2002.
Electronic publications
[9] Duchin JS. Can preparedness for biological 
terrorism save us from pertussis? Arch Pediatr 
Adolesc Med 2004;158(2). Available at http://
archpedi.ama-assn.org/cgi/content/full/158/2/106. 
Accessed June 12, 2004.
[10] Smeeth L, Iliffe S. Community screening for 
visual impairment in the elderly. Cochrane Database 
Syst Rev 2002(2):CD001054. Doi:10.1002/14651858.
CD1001054.
Thesis
[11] Ayers AJ. Retention of resin restorations by 
means of enamel etching and by pins. MSD thesis, 
Indiana University, Indianapolis, 1971.
Website
[12] American Association of Oral and Maxillofacial 
Surgeons. Wisdom teeth. Rosemont, IL: AAOMS, 
2008. Available at http://www.aaoms.org/wisdom_
teeth.php. Accessed November 15, 2008.
Company/manufacturer publication/pamphlet
[13] Eastman Kodak Company, Eastman Organic 
Chemicals.	Catalog	no.	49.	Rochester,	NY:	Eastman	
Kodak; 1977, p. 2–3.
9.8. Tables
Tables should supplement, not duplicate, the text. 
They should have a concise table heading, be self-
explanatory, and numbered consecutively in the 
order of their citation in the text. Items requiring 
explanatory footnotes should be denoted using 
superscripted lowercase letters (a, b, c, etc.), 
with the footnotes arranged under the table in 
alphabetical	order.	Asterisks	(*,	**)	are	used	only	to	
indicate the probability level of tests of significance. 
Abbreviations used in the table must be defined and 
placed after the footnotes in alphabetical order. If 
you include a block of data or table from another 
source, whether published or unpublished, you 
must acknowledge the original source.
9.9. Figures
9.9.1. General guidelines
The number of figures should be restricted to the 
minimum necessary to support the textual material. 
Figures should have an informative figure legend and 
be numbered in the order of their citation in the text. 
All symbols and abbreviations should be defined in 
the figure legend in alphabetical order. Items requiring 
explanatory footnotes should follow the same style as 
that for tables as described in Section 9.7.
Patient identification should be obscured. All 
lettering should be done professionally and should 
be in proportion to the drawing, graph or photograph. 
Photomicrographs must include an internal scale 
marker, and the legend should state the type of 
specimen, original magnification and stain.
Figures must be submitted as separate picture 
files, at the correct resolution (see Section 9.8.2.) 
and named according to the figure number and 
format, e.g., “Fig1.tif”, “Fig2.jpg”.
9.9.2. Formats
Regardless of the application used, when your 
electronic artwork is finalized, please “save as” or 
convert the images to one of the following formats 
(note the resolution requirements for line drawings, 
halftones, and line/halftone combinations given 
below):
•	 	EPS:	vector	drawings.	Embed	the	font	or	save	the	
text as “graphics”.
•	 	TIFF:	color	or	grayscale	photographs	(halftones)—
use a minimum of 300 dpi.
•	 	TIFF:	bitmapped	line	drawings—use	a	minimum	
of 1000 dpi.
•	 	TIFF:	 combination	 of	 bitmapped	 line/halftone	
(color or grayscale)—use a minimum of 600 dpi.
•	 	DOC,	 XLS	 or	 PPT:	 if	 your	 electronic	 artwork	
is created in any of these Microsoft Office 
applications, please supply “as is”.
Please do not:
•	 	Supply	 files	 that	 do	 not	 meet	 the	 resolution	
requirements detailed above;
•	 	Supply	 files	 that	 are	 optimized	 for	 screen	 use	
(such as GIF, BMP, PICT, WPG) as the resolution is 
too low;
•	 	Submit	graphics	that	are	disproportionately	large	
for the content.
A detailed guide on electronic artwork is available at 
www.elsevier.com/artworkinstructions. Please note that 
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